PetIQ, Inc. (NASDAQ:PETQ) Position Cut by Allianz Asset Management GmbH

Allianz Asset Management GmbH lessened its holdings in shares of PetIQ, Inc. (NASDAQ:PETQFree Report) by 16.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 375,640 shares of the company’s stock after selling 74,065 shares during the quarter. Allianz Asset Management GmbH owned about 1.28% of PetIQ worth $7,419,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PETQ. DekaBank Deutsche Girozentrale bought a new position in PetIQ during the fourth quarter valued at about $50,000. AJOVista LLC bought a new stake in shares of PetIQ in the 4th quarter worth approximately $65,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of PetIQ by 351.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,372 shares of the company’s stock worth $67,000 after purchasing an additional 2,625 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in PetIQ during the fourth quarter valued at approximately $177,000. Finally, SG Americas Securities LLC boosted its holdings in PetIQ by 75.1% during the fourth quarter. SG Americas Securities LLC now owns 10,054 shares of the company’s stock worth $199,000 after buying an additional 4,311 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

PetIQ Stock Performance

Shares of PETQ opened at $20.65 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.42 and a debt-to-equity ratio of 1.84. PetIQ, Inc. has a 12 month low of $13.04 and a 12 month high of $22.98. The company’s fifty day moving average is $18.23 and its 200-day moving average is $18.10. The firm has a market cap of $614.34 million, a price-to-earnings ratio of 93.87 and a beta of 1.76.

PetIQ (NASDAQ:PETQGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.17. PetIQ had a return on equity of 13.33% and a net margin of 0.66%. The business had revenue of $308.44 million for the quarter, compared to the consensus estimate of $302.16 million. Equities analysts expect that PetIQ, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PETQ. Jefferies Financial Group increased their price objective on PetIQ from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of PetIQ in a research report on Friday, May 10th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PetIQ currently has an average rating of “Buy” and a consensus target price of $29.00.

Get Our Latest Stock Analysis on PETQ

PetIQ Profile

(Free Report)

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.

Featured Articles

Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQFree Report).

Institutional Ownership by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.